Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 10/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | HTR7 | P34969 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276351 | 0.90 | ADRA2C (0.46) | ADRA2CHTR6DRD2HTR7HTR2A | |
| SCHEMBL18060648 | 0.78 | PLK4 (0.46) | MEN1KMT2A | |
| SCHEMBL12806446 | 0.78 | ADRA2C (0.49) | ADRA2CHTR6DRD2HTR7HTR2A | |
| SCHEMBL1276167 | 0.75 | SMN1; SMN2 (0.44) | DRD2MEN1KMT2AEGFR | |
| SCHEMBL1275994 | 0.73 | NPC1 (0.48) | MEN1KMT2AEGFR | |
| SCHEMBL12805704 | 0.73 | HTR3A (0.46) | ADRA2CHRH4HTR3AMEN1KMT2A | |
| SCHEMBL12806277 | 0.71 | HRH4 (0.49) | HTR6HRH4MEN1KMT2A | |
| SCHEMBL18084078 | 0.71 | ADRA2C (0.39) | ADRA2CHTR6DRD2HTR7HTR2A | |
| SCHEMBL1275384 | 0.71 | RAB9A (0.47) | MEN1KMT2A | |
| SCHEMBL12806084 | 0.71 | UCHL3 (0.51) | HTR1AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2017-06-15 | — | — | US | disclosed |
| US-9567318-B2 | Substituted pyrimidine compounds and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-14 | — | — | US | disclosed |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165265-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | ADRA2C 3502/4885HTR6 1594/4885DRD2 4575/4885 |
| US-20120252818-A1 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME | HSPBP1, HSF1, HSPA2 | ADRA2C 3502/4885HTR6 1594/4885DRD2 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.